Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NADGL · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| NADGL | DEVICE | - |
Inclusion Criteria: * bilateral nasolabial folds with severity score of 3 or 4 on the 6 point scale. Exclusion Criteria: * pregnant/lactating women * subjects who have an allergy to lidocaine or other amide-type anesthetics
NADGL is an investigational product studied for the correction of facial wrinkles, specifically nasolabial folds (NLFs), which are the lines that run from the sides of the nose to the corners of the mouth. It is being developed by Sanofi (SNY) and is currently in Phase 3 clinical development.
NADGL is being developed by Sanofi, a global biopharmaceutical company traded on the stock exchange under the ticker SNY. The product is currently in Phase 3 clinical development for the correction of facial wrinkles, specifically nasolabial folds.
NADGL is in Phase 3 clinical development. It is an investigational product and has not been approved by regulatory authorities. A Phase 3 clinical trial for the correction of nasolabial folds has been completed, but the product remains under investigation.
NADGL has been studied in a completed Phase 3 clinical trial registered as NCT00417469. This trial, conducted in the United States, enrolled 45 participants to compare subject comfort during and after injections with the study products and to evaluate the safety of the product for the correction of nasolabial folds.
NADGL is an investigational product being developed for the correction of facial wrinkles, specifically nasolabial folds. It is not the same as other approved wrinkle treatments, as it is still in clinical development and has not been approved for use. Its safety and efficacy are being evaluated in clinical trials.